title: Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
abstract: OBJECTIVE
  Nilotinib is a selective tyrosine kinase inhibitor of c-Kit, Abl and platelet-derived growth factor receptor-α/β. To evaluate nilotinib's potential use as a treatment of human ovarian cancer, we tested nilotinib's preclinical activity in ovarian cancer cell lines with different tyrosine kinase expression patterns.
  
  
  METHODS
  The effects of nilotinib on ovarian cancer cell growth were studied alone and in combination with carboplatin and paclitaxel. Proapoptotic and antimigratory effects were examined using TUNEL and migration assays.
  
  
  RESULTS
  Nilotinib alone and in combination with carboplatin and paclitaxel significantly inhibited cell growth in PDGFR-α-positive ovarian cancer cell lines. The combination of nilotinib with carboplatin and paclitaxel showed synergistic effects on cell proliferation. Nilotinib treatment led to the inhibition of cell migration alone and in combination with carboplatin and paclitaxel. Apoptosis induction occurred in response to nilotinib that increased in combination with carboplatin.
  
  
  CONCLUSIONS
  Nilotinib may be a feasible targeted therapy option for the treatment of ovarian cancer.
authors.affiliation: Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
authors.forename: Marion T
authors.initials: MT
authors.lastname: Weigel
authors.forename: Katrin
authors.initials: K
authors.lastname: Rath
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Alkatout
authors.forename: Antonia S
authors.initials: AS
authors.lastname: Wenners
authors.forename: Christian
authors.initials: C
authors.lastname: Schem
authors.forename: Nicolai
authors.initials: N
authors.lastname: Maass
authors.forename: Walter
authors.initials: W
authors.lastname: Jonat
authors.forename: Christoph
authors.initials: C
authors.lastname: Mundhenke
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D016190:Carboplatin; D020796:Receptor, Platelet-Derived Growth Factor alpha; C498826:nilotinib; D017239:Paclitaxel